Methadone Compounded Solution

Effective September 1, 2014 

Reimbursement of Compounded Methadone solution for the treatment of opioid dependence will be considered for patients who meet the following criteria:

1. Patient has demonstrated that they have experienced a true allergy to both commercially available Methadose formulations (i.e., Methadose 10 mg/mL oral cherry flavoured concentrate AND Methadose 10 mg/mL dye-free, sugar-free, unflavoured oral concentrate).

2. The request must be accompanied by a completed Health Canada adverse drug reaction form (Canada Vigilance Adverse Reaction Reporting Form) and include a detailed description of the allergic reaction to each Methadose product, a description of the circumstances in which the reactions occurred, and demonstration that the allergy is unlikely to be related to any diluent in which Methadose was mixed, but rather, that it was caused by the excipients within the Methadose formulation.

EAP Drug Request Form:

Standard Form for EAP Drug Requests